Target Price | $525.30 |
Price | $468.85 |
Potential | 12.04% |
Number of Estimates | 30 |
30 Analysts have issued a price target Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals target price is $525.30. This is 12.04% higher than the current stock price. The highest price target is $652.05 39.07% , the lowest is $333.30 28.91% . | |
A rating was issued by 40 analysts: 24 Analysts recommend Vertex Pharmaceuticals to buy, 15 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2026 of 12.04% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
35 Analysts have issued a sales forecast Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals sales estimate is $12.2b . This is 9.63% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.9b 15.85% , the lowest is $11.5b 3.77% .
This results in the following potential growth metrics:
2024 | $11.0b | 11.66% |
---|---|---|
2025 | $12.2b | 10.43% |
2026 | $13.5b | 10.81% |
2027 | $14.7b | 9.10% |
2028 | $15.8b | 7.11% |
2029 | $18.0b | 14.51% |
2030 | $20.1b | 11.11% |
2031 | $21.3b | 6.05% |
2032 | $23.5b | 10.68% |
13 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2025. The average Vertex Pharmaceuticals EBITDA estimate is $5.6b . This is 26.68% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.3b 43.53% , the lowest is $4.4b 0.06% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.6b | 1.37% |
---|---|---|
2025 | $5.6b | 21.39% |
2026 | $6.8b | 21.64% |
2027 | $7.4b | 9.28% |
2028 | $7.9b | 6.14% |
2029 | $8.8b | 11.20% |
2030 | $9.6b | 8.97% |
2031 | $10.2b | 6.75% |
2032 | $11.7b | 14.56% |
2024 | 41.77% | 9.21% |
---|---|---|
2025 | 45.91% | 9.92% |
2026 | 50.40% | 9.78% |
2027 | 50.48% | 0.16% |
2030 | 47.64% | 1.93% |
2031 | 47.95% | 0.65% |
2032 | 49.63% | 3.50% |
37 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Vertex Pharmaceuticals net profit estimate is $4.7b . This is 575.64% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $5.1b 612.68% , the lowest is $4.3b 530.37% .
This results in the following potential growth metrics and future Net Margins:
2024 | $-536m | 114.80% |
---|---|---|
2025 | $4.7b | 978.19% |
2026 | $5.4b | 15.30% |
2027 | $6.0b | 10.93% |
2030 | $8.4b | 9.09% |
2031 | $8.9b | 6.28% |
2032 | $10.1b | 13.39% |
2024 | -4.86% | 113.25% |
---|---|---|
2025 | 38.65% | 895.23% |
2026 | 40.22% | 4.06% |
2027 | 40.89% | 1.67% |
2030 | 41.89% | 1.80% |
2031 | 41.98% | 0.21% |
2032 | 43.00% | 2.43% |
37 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is $18.30 . This is 580.31% higher than earnings per share in the financial year 2024. The highest EPS forecast is $19.73 617.85% , the lowest is $16.56 534.65% .
This results in the following potential growth metrics and future valuations:
2024 | $-2.08 | 114.97% |
---|---|---|
2025 | $18.30 | 979.81% |
2026 | $21.10 | 15.30% |
2027 | $23.41 | 10.95% |
2028 | $25.10 | 7.22% |
2029 | $29.96 | 19.36% |
2030 | $32.68 | 9.08% |
2031 | $34.73 | 6.27% |
2032 | $39.39 | 13.42% |
Current | -123.06 | 50.99% |
---|---|---|
2025 | 25.61 | 120.81% |
2026 | 22.22 | 13.24% |
2027 | 20.03 | 9.86% |
2030 | 14.35 | 8.31% |
2031 | 13.50 | 5.92% |
2032 | 11.90 | 11.85% |
Based on analysts' sales estimates for 2025, the Vertex Pharmaceuticals stock is valued at an EV/Sales of 9.39 and an P/S ratio of 9.89 .
This results in the following potential growth metrics and future valuations:
Current | 10.30 | 9.01% |
---|---|---|
2025 | 9.39 | 8.80% |
2026 | 8.48 | 9.76% |
2027 | 7.77 | 8.34% |
2030 | 5.70 | 10.00% |
2031 | 5.38 | 5.71% |
2032 | 4.86 | 9.65% |
Current | 10.85 | 8.42% |
---|---|---|
2025 | 9.89 | 8.79% |
2026 | 8.93 | 9.76% |
2027 | 8.18 | 8.34% |
2030 | 6.01 | 10.00% |
2031 | 5.66 | 5.71% |
2032 | 5.12 | 9.65% |
Vertex Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Jun 23 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jun 20 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Jun 17 2025 |
Leerink Partners |
Outperform
➜
Market Perform
|
Downgrade | May 06 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | May 06 2025 |
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | May 06 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | May 06 2025 |
Analyst Rating | Date |
---|---|
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Jun 23 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jun 20 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Jun 17 2025 |
Downgrade
Leerink Partners:
Outperform
➜
Market Perform
|
May 06 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
May 06 2025 |
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
May 06 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
May 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.